Pharmaco - Press Releases

Date	Title	Company
28-Jul-2022	Biotest AG: Biotest increases EBITDA in first half-year by 52% to 8.8 million EUR	Biotest AG
28-Jul-2022	Drägerwerk AG & Co. KGaA: Dräger expects significant recovery in business development in the second half of 2022	Drägerwerk AG & Co. KGaA
28-Jul-2022	Spexis provides business update	Spexis AG
28-Jul-2022	Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance	Cosmo Pharmaceuticals N.V.
28-Jul-2022	Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease	Relief Therapeutics Holding SA
28-Jul-2022	Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China	Cosmo Pharmaceuticals N.V.
28-Jul-2022	Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs	Relief Therapeutics Holding SA
27-Jul-2022	Fresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised	Fresenius SE & Co. KGaA
27-Jul-2022	Fresenius Medical Care AG & Co. KGaA cuts outlook for FY 2022 due to increased headwinds from U.S. labor market situation and global inflation, and withdraws 2025 targets	Fresenius Medical Care AG & Co. KGaA
27-Jul-2022	MagForce AG: Provisional insolvency administrator appointed by the court	MagForce AG
27-Jul-2022	Original-Research: MagForce AG (von GBC AG)	MagForce AG
27-Jul-2022	Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter	Eckert & Ziegler Strahlen- und Medizintechnik AG
26-Jul-2022	MagForce AG: Application for the Opening of Insolvency Proceedings	MagForce AG
26-Jul-2022	Pleco Therapeutics Announces Expansion with the Incorporation of a U.S. Subsidiary and the Appointment of Michael Stalhamer as President	Pleco Therapeutics
26-Jul-2022	SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)	B3C newswire
26-Jul-2022	Developing a Variant-Proof SARS-CoV-2 Vaccine: a CEPI-funded ExcellGene Partnership with Bharat Biotech and the University of Sydney	B3C newswire
26-Jul-2022	First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations	AstraZeneca
26-Jul-2022	MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022	MorphoSys AG
26-Jul-2022	Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022	MorphoSys AG
26-Jul-2022	Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia	Cosmo Pharmaceuticals N.V.